enVVeno Medical Corp
NVNONasdaqCIK 1661053HealthcareFiscal year ends Dec 31
Reports and events: 132 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-10-2917:00 ET | DEF 14A | Proxy statementPeriod 2026-12-10 | 0001140361-26-041182 |
| 2026-10-2916:05 ET | 10-Q | Quarterly reportPeriod 2026-09-30 | 0001493152-26-049269 |
| 2026-09-1516:01 ET | SCHEDULE 13D/A | Ownership report, active investor, amended | 0001213900-26-100114 |
| 2026-07-3016:05 ET | 10-Q | Quarterly reportPeriod 2026-06-30 | 0001493152-26-035452 |
| 2026-07-1416:55 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-033193 |
| 2026-05-0616:10 ET | 10-Q | Quarterly reportPeriod 2026-03-31 | 0001493152-26-021490 |
| 2026-04-2908:25 ET | 8-K | 2.02 Results of operations; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-26-019485 |
| 2026-03-2616:24 ET | 10-K | Annual reportPeriod 2025-12-31 | 0001493152-26-012928 |
| 2026-02-2009:43 ET | SCHEDULE 13D | Ownership report, active investor | 0001213900-26-018626 |
| 2026-02-2009:43 ET | SCHEDULE 13D | Ownership report, active investor | 0001213900-26-018625 |
| 2026-02-0408:30 ET | 8-K | 2.02 Results of operations; 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-26-005030 |
| 2026-01-2016:10 ET | 8-K | 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0001493152-26-002860 |
| 2025-12-1216:05 ET | 8-K | 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001493152-25-027482 |
| 2025-11-2017:18 ET | 8-K | 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0001493152-25-024494 |
| 2025-11-1421:29 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-25-022440 |
| 2025-10-3017:28 ET | 8-K | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001493152-25-020276 |
| 2025-10-3016:16 ET | DEF 14A | Proxy statementPeriod 2025-12-11 | 0001140361-25-039863 |
| 2025-10-3016:06 ET | 10-Q | Quarterly reportPeriod 2025-09-30 | 0001493152-25-020215 |
| 2025-10-1006:30 ET | 8-K | 3.01 Delisting notice; 9.01 Financial statements and exhibits | 0001493152-25-017691 |
| 2025-08-2007:10 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-25-012181 |
| 2025-07-3116:25 ET | 10-Q | Quarterly reportPeriod 2025-06-30 | 0001493152-25-011521 |
| 2025-05-2016:30 ET | 8-K | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001641172-25-011729 |
| 2025-04-3017:28 ET | 10-Q | Quarterly reportPeriod 2025-03-31 | 0001641172-25-007908 |
| 2025-04-2116:05 ET | 8-K | 4.01 Change of auditor; 9.01 Financial statements and exhibits | 0001641172-25-005547 |
| 2025-02-2817:23 ET | 10-K/A | Annual report, amendedPeriod 2024-12-31 | 0001493152-25-008739 |
| 2025-02-2821:37 ET | 10-K | Annual reportPeriod 2024-12-31 | 0001493152-25-008581 |
| 2024-12-2619:10 ET | 8-K | 5.07 Shareholder vote results | 0001493152-24-051926 |
| 2024-11-1916:45 ET | DEF 14A | Proxy statementPeriod 2024-12-18 | 0001140361-24-047305 |
| 2024-10-3119:20 ET | 10-Q | Quarterly reportPeriod 2024-09-30 | 0001493152-24-043100 |
| 2024-09-3017:05 ET | 8-K | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001493152-24-038828 |
| 2024-07-3116:05 ET | 10-Q | Quarterly reportPeriod 2024-06-30 | 0001493152-24-029737 |
| 2024-05-0816:05 ET | 10-Q | Quarterly reportPeriod 2024-03-31 | 0001493152-24-018225 |
| 2024-04-2406:15 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-24-015752 |
| 2024-03-0608:40 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-24-008950 |
| 2024-02-2916:29 ET | 10-K | Annual reportPeriod 2023-12-31 | 0001493152-24-008336 |
| 2023-12-0716:05 ET | 8-K | 5.07 Shareholder vote results | 0001493152-23-044010 |
| 2023-11-1608:45 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-23-041594 |
| 2023-11-0316:05 ET | DEF 14A | Proxy statementPeriod 2023-11-03 | 0001493152-23-039303 |
| 2023-10-2617:58 ET | 10-Q | Quarterly reportPeriod 2023-09-30 | 0001493152-23-038302 |
| 2023-10-1217:00 ET | 8-K | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001493152-23-037065 |
| 2023-07-3116:30 ET | 10-Q | Quarterly reportPeriod 2023-06-30 | 0001493152-23-026085 |
| 2023-04-2816:05 ET | 10-Q | Quarterly reportPeriod 2023-03-31 | 0001493152-23-014683 |
| 2023-03-0216:47 ET | 10-K | Annual reportPeriod 2022-12-31 | 0001493152-23-006587 |
| 2022-12-0616:15 ET | 8-K | 5.07 Shareholder vote results | 0001493152-22-034589 |
| 2022-11-0117:29 ET | DEF 14A | Proxy statementPeriod 2022-11-01 | 0001493152-22-030124 |
| 2022-10-2716:05 ET | 10-Q | Quarterly reportPeriod 2022-09-30 | 0001493152-22-029717 |
| 2022-08-0316:26 ET | 10-Q | Quarterly reportPeriod 2022-06-30 | 0001493152-22-021166 |
| 2022-05-1116:15 ET | 10-Q/A | Quarterly report, amendedPeriod 2022-03-31 | 0001493152-22-012858 |
| 2022-05-1116:10 ET | 10-K/A | Annual report, amendedPeriod 2021-12-31 | 0001493152-22-012855 |
| 2022-04-2916:41 ET | 10-Q | Quarterly reportPeriod 2022-03-31 | 0001493152-22-011591 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 29, 2026, 19:27 ET. Listed shows no prices and gives no investment advice.